We are thrilled to announce that John Muir Health-Walnut Creek has been officially selected as one of 32 hospitals around the world to enroll patients in the MEMBRANE trial, a groundbreaking study sponsored by Cerenovus, part of the Johnson & Johnson family of healthcare medical companies. No other hospital in Northern California has been selected. This is a pivotal moment for our community and for advancements in medical treatments.
Selected to lead this innovative trial at our site is Dr. Benjamin Yim, MD and his appointment as the Site Principal Investigator is a testament to his dedication and expertise in medical research and patient care.
About the MEMBRANE Trial
The MEMBRANE trial is focused on exploring the benefits of middle meningeal artery embolization in the treatment of chronic or mixed density subdural hematomas. This approach has shown promise in improving patient outcomes, reducing complications, and offering a minimally invasive treatment option.
Benefits of Middle Meningeal Artery Embolization
Middle meningeal artery embolization has been recognized for its potential benefits in treating subdural hematomas, including:
- Reduced risk of recurrence
- Minimally invasive procedure
- Shorter recovery times
- Improved overall outcomes for patients
More Information
Read more about the Ceronovus MEMBRANE Study:
- CERENOVUS Announces First Patient Enrolled in MEMBRANE Study on Chronic Subdural Hematomas
- Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA (MEMBRANE)
- Cerenovus’ TruFill n-BCA Liquid Embolic System Evaluated for Treatment of Chronic Subdural Hematoma
Together, we can make a difference in the lives of those affected by chronic or mixed-density subdural hematomas.
